NCT05562219View on ClinicalTrials.gov

QA108 Phase II Study in Subjects With Intermediate Age-Related Macular Degeneration

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

June 29, 2022

Primary Completion Date

June 24, 2024

Study Completion Date

June 24, 2024

Conditions
Intermediate Age-Related Macular Degeneration
Interventions
DRUG

QA108 granules

Take the medication as required for 24 weeks

DRUG

QA108 granules placebo

Take the medication as required for 24 weeks

Trial Locations (1)

Unknown

Peking Union Medical College Hospital (PUMCH), Beijing

All Listed Sponsors
lead

Smilebiotek Zhuhai Limited

INDUSTRY